RecruitingEarly Phase 1NCT04139304

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Studying Plasmablastic lymphoma

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: AIDS Malignancy Consortium
Principal Investigator: Ariela Noy, MD
Memorial Sloan Kettering Cancer Center
Intervention: Cyclophosphamide(drug)
Enrollment: 15 enrolled
Eligibility: 18 years · All sexes
Timeline: 2021 – 2030

Study locations (8)

University of Miami Miller School of Medicine, Miami, Florida, United States
University of Illinois at Chicago, Chicago, Illinois, United States
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
The Ohio State University, Columbus, Ohio, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Collaborators

National Cancer Institute (NCI) · Janssen Scientific Affairs, LLC · Montefiore Medical Center · Memorial Sloan Kettering Cancer Center · AIDS and Cancer Specimen Resource · The Emmes Company, LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04139304 on ClinicalTrials.gov

Other trials for Plasmablastic lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Plasmablastic lymphoma →

← Back to all trials